Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.2% Today

What is Amylyx Pharmaceuticals?

Asset Amylyx Pharmaceuticals (NASDAQ: AMLX) is a pharmaceutical company focused on developing treatments for neurodegenerative diseases. The company is currently working on avexitide, a potential drug candidate.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.2% on Feb 11, 2026 16:16

• Positive forecasts and a raised price target did not prevent a bearish movement in the stock of Amylyx Pharmaceuticals (AMLX).
• Insider transactions, with a director buying shares and the CEO selling some, may have contributed to investor uncertainty.
• Despite strong financial health and significant cash reserves, Amylyx Pharmaceuticals is not yet profitable.
• The market's cautious response to the company's path to avexitide approval, despite a "structurally de-risked" trial design, led to the downward trend in the stock price.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx stock price target raised to $28 from $20 at H.C. Wainwright By Investing.com

H.C. Wainwright has increased its price target for Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) to $28 from $20, maintaining a Buy rating. This adjustment reflects a "structurally de-risked path to approval" for Amylyx’s avexitide, based on the LUCIDITY trial design, and an estimated 97% upside from the current stock price. Despite not yet being profitable, the company demonstrates strong financial health with significant cash reserves.

https://za.investing.com/news/analyst-ratings/amylyx-stock-price-target-raised-to-28-from-20-at-hc-wainwright-93CH-4105979

HC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price

HC Wainwright has reiterated a "buy" rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) and raised its price target from $20 to $28, indicating a potential 96.9% upside. This positive outlook aligns with a "Moderate Buy" consensus among analysts, though individual ratings vary. Insider transactions show varied activity, with a director purchasing shares and the CEO selling some, while institutional ownership remains high.

https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-amylyx-pharmaceuticals-nasdaqamlx-stock-price-2026-02-10/

Trending Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.4% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 31.3% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.1% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.1% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.3% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 9.8% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.8% Today

Chemours Company (The) ($CC) Stock Forecast: Down 18.3% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 5.2% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

Amylyx Pharmaceuticals Price History

07.00.2026 - AMLX Stock was up 7.6%

• The positive movement in AMLX stock today is likely fueled by the company's commitment to developing novel therapies to address medical gaps.
• Despite a recent 7.2% decline in stock price, analysts maintain a "Moderate Buy" consensus on AMLX, setting a target price of $17.25. This mixed sentiment may have prompted profit-taking and renewed investor interest.
• Investor optimism regarding AMLX's future may stem from its earnings beat last quarter, substantial institutional ownership, and ongoing endeavors in developing new therapies.
• Market dynamics might also show investor confidence in Amylyx Pharmaceuticals' strategic objectives and the potential impact of its innovative therapies on the healthcare industry, leading to an increase in the stock price.

20.00.2026 - AMLX Stock was up 5.8%

• Insider selling of shares worth US$2.0 million despite a 15% gain this week may suggest potential concerns about future weakness in the stock.
• The fact that insiders are selling shares at or below the current trading price could indicate a lack of confidence in the stock's valuation.
• Despite some insider buying activity, the overall trend of selling outweighing buying implies a bearish sentiment among insiders regarding the stock's future performance.
• This insider activity might have contributed to the bullish movement in AMLYX today, as investors could be interpreting it as a signal of potential positive developments or upcoming news that could drive the stock price higher.

20.00.2026 - AMLX Stock was up 15.4%

• The selection of AMX0318 as a new development candidate for rare endocrine diseases is believed to have spurred a positive reaction and optimism from investors regarding the company's future pipeline.
• Despite some insider selling amidst the recent stock price growth, the market's response to the new development candidate appears to have overshadowed these worries, resulting in the stock's upward movement.
• Investors may view the appointment of AMX0318 as a signal of Amylyx Pharmaceuticals' dedication to innovation and expansion, fueling interest in the stock.
• The company's strategic emphasis on tackling unmet medical requirements in rare diseases could be interpreted as a favorable long-term investment opportunity, contributing to the positive market activity of AMLX.

09.00.2026 - AMLX Stock was up 5.7%

• The positive news surrounding the selection of AMX0318 as a promising development candidate has contributed to the bullish movement in AMLX stock, suggesting potential growth and innovation in the company's pipeline.
• Collaboration with Gubra A/S may lead to over $50 million in milestones and royalties, enhancing investor confidence in Amylyx Pharmaceuticals' strategic partnerships and revenue streams.
• Despite a recent 7.2% decline in stock price, analysts maintaining a "Moderate Buy" consensus rating and a target price above the current trading value indicate a positive market sentiment, reflecting long-term potential for the company's therapy development.
• Amylyx Pharmaceuticals' focus on addressing healthcare challenges and dedication to developing novel therapies for unmet medical needs reinforce its position in the biopharmaceutical industry, potentially sustaining investor interest and stock performance.

14.00.2026 - AMLX Stock was up 6.9%

• The selection of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases has generated positive sentiment and excitement among investors.
• The promising preclinical properties and pharmacokinetic profile of AMX0318, along with the collaboration with Gubra A/S, have contributed to the bullish trend.
• Analysts' positive outlook, such as Mizuho reiterating an Outperform rating and raising price targets, has further fueled investor confidence in Amylyx Pharmaceuticals and its future prospects.
• The anticipation of advancing AMX0318 into IND-enabling studies and the upcoming Phase 3 LUCIDITY trial for avexitide in Q3 2026 are key catalysts driving the bullish momentum for AMLX.

21.00.2026 - AMLX Stock was up 10.8%

• AMLX stock witnessed a strong uptrend, rising by 8.85% on January 20th and peaking at $15.57 during the trading day.
• The upswing in the stock price is linked to the selection of AMX0318 as a potential treatment for rare endocrine disorders, signaling the company's dedication to broadening its product portfolio.
• Despite notable selling of shares by company co-CEOs for managing option expenses and taxes, positive market sentiment persists due to Mizuho's endorsement and confidence in AMLX's GLP-1 initiative and product pipeline.
• Analysts foresee a target price averaging $20.22, representing a potential 29.92% increase, endorsed by the general "Buy" stance from brokerage entities, reinforcing a positive outlook for AMLX stock.

04.01.2026 - AMLX Stock was down 6.2%

• The Co-Chief Executive Officer selling a significant amount of AMLX shares to cover option costs and tax obligations likely raised concerns among investors, indicating lack of confidence in the stock.
• The ongoing investigations into alleged breaches of fiduciary duties by Amylyx Pharmaceuticals officers and directors could have contributed to the negative sentiment surrounding the stock.
• Shareholders being encouraged to discuss their rights and potential legal actions against the company's management might have added to the uncertainty and selling pressure on AMLX shares.
• The combination of executive selling, fiduciary duty investigations, and shareholder rights discussions could have created a perfect storm of negative news leading to the bearish movement in AMLX stock today.

11.01.2026 - AMLX Stock was down 5.2%

• Positive forecasts and a raised price target did not prevent a bearish movement in the stock of Amylyx Pharmaceuticals (AMLX).
• Insider transactions, with a director buying shares and the CEO selling some, may have contributed to investor uncertainty.
• Despite strong financial health and significant cash reserves, Amylyx Pharmaceuticals is not yet profitable.
• The market's cautious response to the company's path to avexitide approval, despite a "structurally de-risked" trial design, led to the downward trend in the stock price.

28.00.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX today could be attributed to insider selling activities, with 157,783 shares sold in the past 90 days, potentially signaling lack of confidence from within the company.
• Despite positive analyst sentiment and a high price target, the recent insider selling totaling over $2.12 million in the last quarter might have spooked investors, leading to the bearish movement.
• The news of Gubra securing milestones and royalties from Amylyx Pharmaceuticals could have also impacted the stock negatively, as it highlights potential competition and collaboration dynamics in the industry.
• The stock hitting a 52-week high recently might have prompted profit-taking by investors, contributing to the bearish movement as traders lock in gains.

16.00.2026 - AMLX Stock was up 6.5%

• AMLX stock surged today following the announcement of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. This positive news regarding the expansion of their pipeline beyond neurology and into rare diseases has likely fueled investor optimism.
• The selection of AMX0318, a long-acting GLP-1 receptor antagonist with promising preclinical properties, signifies a strategic move by Amylyx Pharmaceuticals to diversify its portfolio and address unmet medical needs in different therapeutic areas.
• Investors seem to be responding favorably to the company's proactive approach in advancing AMX0318 towards IND-enabling studies and the upcoming topline data release from the Phase 3 LUCIDITY trial for avexitide, indicating confidence in the company's future growth prospects.
• Amylyx Pharmaceuticals' strategic decision to enter the rare diseases market and broaden its focus beyond neurology has likely reshaped its investment narrative, attracting attention from investors looking for opportunities in the biopharmaceutical sector.

23.00.2026 - AMLX Stock was down 6.9%

• Amylyx Pharmaceuticals (AMLX) observed a decrease in stock value despite achieving a new 52-week high and notable growth in the past year.
• The announcement of Gubra securing milestones and royalty upside for AMX0318, a GLP-1 receptor antagonist, raised concerns about potential competition or market saturation in the pharmaceutical sector.
• Insider selling by the CEO and other executives, surpassing $2 million, may have indicated a lack of confidence in the company's future, leading to stock price decline.
• Despite advancements in its drug pipeline and financial position, concerns about market saturation, coupled with insider selling, likely prompted profit-taking and a bearish sentiment among investors.

30.00.2026 - AMLX Stock was down 5.6%

• There is an ongoing investigation regarding potential breaches of fiduciary duties by certain officers and directors of Amylyx Pharmaceuticals, which may have prompted investor concerns and a subsequent sell-off.
• While HC Wainwright offered a positive earnings estimate for FY2030, insider selling of shares and an uptick in institutional holdings could have spurred uncertainty and contributed to the downward trend.
• Analysts have given an average recommendation of "Moderate Buy" for the stock, and with the stock trading above its moving averages, mixed sentiments in the market may have led to a lack of clear direction and the ensuing decline in stock value.